Meriden woman with rare brain condition inspires others on social media
HARTFORD, Conn. (WTNH) — A Connecticut woman had no idea she had a rare brain condition since birth until she passed out and was flown to Hartford Hospital, where she would end up needing four surgeries.
'My mom had said that I came to her with a regular headache and she said within a matter of five minutes, I had passed out,' 26-year-old Michaela Williams of Meriden said. That jumpstarted her emergency medical ordeal.
Dr. Eric Sussman, a Hartford Hospital neurosurgeon helped save her life. It turns out that Williams was among just 1% of the population to have a condition called arteriovenous malformation, or AVM. It is abnormal tangles of high pressure blood vessels in her brain. They flowed into delicate arteries which started to bleed under pressure. 'Removing the AVM is very, I think, one of the more complex surgeries that we do. But in her case it was just the whole clinical picture of her being sick and really teetering on the edge the whole time she was here,' Sussman, who specializes in vascular surgery, said.
Sussman says Williams underwent four surgeries, including a craniotomy, where part of her skull was removed to allow her brain to heal for a period of time. Williams' strength and faith pulled her through. Sussman calls it miraculous. 'I'm still creative. I like to write. I like to paint. I like to go outside,' Williams said, who continues to make uplifting TikTok videos like she did before her diagnosis.
She hopes to help others who may be going through a tough time. 'I want them to feel encouraged, understood, heard. I want them to feel like they're not the only one,' Williams said.She would like to make a dating app for others living with brain injuries.'Everybody that follows me on TikTok, they are family. They encourage me, they push me, uplift me and we encourage and push and uplift each other,' Williams said.
There are two very positive takeaways from Williams' journey. First, she was very lucky that her mother was home when she first passed out to get her emergency care. Second, Dr. Sussman said that her brain will continue to heal, possibly for a few more years.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Nurse Suddenly Lost Her Sight While Treating Patients. Then Came an Unexpected Diagnosis (Exclusive)
While working in the ER, Breanna T. suddenly lost her vision and kept treating patients as her sight deteriorated She was told it wasn't emergent, but days later, a specialist diagnosed her with acute angle closure glaucoma Breanna's vision has returned, but her story, and viral TikTok, have sparked wider conversations about advocacy and medication side effectsOne moment, Breanna T. was helping patients during a routine emergency room shift, and the next, the world around her was a blur. The ER nurse had no warning before her vision disappeared in both eyes, kicking off a frightening medical mystery that would later go viral on TikTok. In the video, Breanna reenacts what unfolded in those first 48 hours with a pointed 'put a finger down' challenge, recounting how she finished her shift while barely able to see, and the journey that followed before she received a diagnosis. 'I looked up to see who was calling my name, and I couldn't see her at all,' Breanna tells PEOPLE, describing the moment everything changed. 'It was just very shocking to me, because literally 10 seconds before that, I was seeing just fine.' She had just stepped out of a patient's room to assist a fellow nurse when the sudden loss of sight occurred. As panic swelled beneath the surface, her clinical instincts kicked in. 'I cleaned my glasses, I took my blood pressure, I took my blood sugar … I was just trying to go through everything I could think of to fix it,' she says. 'I was also at work, still responsible for helping care for patients, so I was doing my best to keep my composure.' Rather than alerting her team right away, Breanna first tried to troubleshoot the situation herself. She didn't want to raise the alarm until she had ruled out the basics. 'I was like, 'Here's the situation … do you guys have any ideas? Because I've already done everything I can think of,' ' she recalls telling her coworkers and several doctors. 'So then we started spitballing, trying to figure out what else we could test.' She had been trained to recognize red flags for emergencies and was deeply concerned about the possibility of a stroke. But her symptoms weren't fitting into any box. 'Loss of vision is a pretty standard stroke symptom,' she explains. 'But because it was both eyes at the same time and I had no other symptoms, I tried to stay levelheaded.' Her coworkers asked all the right questions, but nothing beyond her vision seemed to be affected. 'People were asking, 'Do you have a headache? Are you nauseous?' But literally, it was just my vision change,' she says. 'So I was honestly at a loss, because this didn't look like the heart attacks, strokes or brain bleeds I've seen before.' After confirming there were no immediate life-threatening causes, the ER team told her to follow up outpatient. As a nurse, Breanna understood why, but as a patient, it felt unsettling. 'I tell patients this all the time, and being on the other side of it was eye-opening,' she says. 'It wasn't life-threatening, but it was still scary not knowing what was going to happen next.' After her shift, she tried to book an urgent appointment with her optometrist, but found herself stuck. She couldn't even get far enough into a conversation to explain why she needed care. 'They'd say, 'We don't have openings,' before I could tell them I was having an emergent vision change,' she says. 'I felt stuck between a rock and a hard place.' With emergency services having done all they could, and no specialist available, she was left waiting and hoping. Her boyfriend began calling providers on her behalf, trying to get her seen. 'It was just really frustrating,' she says. 'I felt like I was being stopped before I was even able to tell anybody why I needed an immediate visit.' In total, Breanna spent five days with severely compromised vision. On the first day, she received contacts that somewhat helped, but even those came with side effects. 'They weren't perfect, and they gave me more headaches than not being able to see,' she says. 'So I was only wearing them when I absolutely had to.' When she finally got an appointment with an optometrist, she decided to go alone. She had no idea just how serious the visit would become. 'He stayed really calm, but started asking questions that felt odd,' she says. 'Then he told me my eye scans didn't look normal. My pressures were way above average, and he could see swelling.' The diagnosis was acute angle closure glaucoma, a rare condition that can come on rapidly and without warning. The optometrist told her she needed to see a specialist immediately or head straight to a hospital with ophthalmology on call. 'It was 4:30 p.m. on a Friday,' Breanna says. 'I was scared I'd have to go back to the ER and start all over again.' Though her boyfriend and mom rushed to be with her, Breanna had faced the alarming news alone. And in that moment, her thoughts went straight to her son. 'I'm a mom. I have a toddler,' she says. 'All I could think was, 'Am I going to be able to see my son grow up?' ' The disease typically takes years to develop, but Breanna had deteriorated within hours. Doctors were optimistic her case would be reversible, but the wait was excruciating. 'I wasn't ready to stop my medication, but that's what ended up solving it,' she says. 'I stopped taking it that day, and by the time it was out of my system, my vision returned.' Her care team believes the antidepressant triggered the event, likely due to an underlying condition. And for Breanna, the timeline made sense. 'The half-life of the medication lined up with when my vision came back,' she says. 'They're almost 99% sure it was [that].' Breanna hadn't been familiar with her diagnosis before that day. Glaucoma wasn't something she had seen often in the ER, especially not in this form. 'The patients I've cared for had long-term glaucoma, with black spots or floaters — not blurry vision like I had,' she says. 'Even the symptoms didn't line up.' At one point, she was even questioned about exposure to rare diseases due to her line of work. Ebola, measles and Lyme disease were all floated. 'I said no, and I still stand by no,' she says. 'But contact tracing takes weeks, so it's still something we may have to revisit.' Still, because her symptoms cleared after stopping the medication, her team now leans heavily toward that explanation. And they found something else along the way. 'I have an enlarged optic nerve on my left side, which predisposes me to glaucoma,' she says. 'That may be why it happened to me and not someone else.' Breanna will now have yearly checkups to monitor her eye health. The goal is early detection should anything change in the future. 'It was an incidental finding, but a good one,' she says. 'Even though my symptoms have resolved, I'm still at risk for developing another type of glaucoma later on.' Returning to work felt emotional and empowering. It reminded her why she became a nurse in the first place. 'I was just grateful to still be able to do my job,' she says. 'I didn't want to lose my career, and I didn't want to lose my motherhood.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. As for advice for others, Breanna wants people navigating confusing health issues to keep advocating for themselves, even when the answers are slow. It only takes one person to listen. 'You're your biggest advocate,' Breanna says. 'You're the only one who can really explain what's going on in your body.' She also acknowledges how often women are dismissed in medical spaces. And though she works in healthcare, she felt it herself. 'Being a woman makes it harder as they're quicker to brush you off,' she says. 'You just have to keep fighting until you find someone who takes you seriously.' Looking back, she wishes more people understood the emotional toll of being caught between not fitting a diagnosis and not getting answers. Her case didn't follow a pattern, which left even doctors unsure where to start. 'If you don't meet the classic symptoms, people don't know where to begin,' she says. 'That doesn't mean you're not sick.' Her TikTok has sparked wide conversation but she never meant to scare anyone. She just wanted to tell the truth. 'I wasn't making that video to tell people to stop their meds,' she says. 'If you're afraid of side effects, that's okay … just talk to your doctor first.' Read the original article on People
Business Upturn
11 hours ago
- Business Upturn
Pliant Therapeutics Provides Update on BEACON-IPF
Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis (IPF). BEACON-IPF Trial Update BEACON-IPF was a randomized, double-blind, placebo-controlled, global Phase 2b/3 clinical trial evaluating patients with IPF. In March of this year, Pliant announced the voluntary discontinuation of BEACON-IPF following a prespecified data review and recommendation by the trial's independent Data Safety Monitoring Board (DSMB), as well as a secondary review and recommendation by an outside expert panel, citing an imbalance in IPF-related adverse events. Following an analysis of the full safety and efficacy data from the BEACON-IPF trial, the Company is discontinuing development of bexotegrast in IPF. Results showed that at doses of 160 mg and 320 mg, bexotegrast demonstrated an unfavorable risk-benefit profile. Compared to placebo, bexotegrast-treated participants showed an increased risk of experiencing adverse events associated with IPF disease progression, defined as events of worsening of IPF and acute IPF exacerbation, respiratory-related hospitalization, and/or all-cause mortality. The average time to disease progression for bexotegrast-treated participants was 33 weeks, suggesting that the safety risk may not be apparent with shorter dosing duration as was the case in the prior INTEGRIS-IPF Phase 2a trial. At Week 12, bexotegrast 160 mg and 320 mg treatment groups demonstrated improvements in forced vital capacity (FVC) decline of 72 mL (p<0.05) and 46 mL (p>0.05), respectively, compared to placebo. At Week 24, bexotegrast 160 mg and 320 mg treatment groups demonstrated improvements in FVC decline of 58 mL (p>0.05) and 8 mL (p>0.05), respectively, compared to placebo. The full results from BEACON-IPF will be submitted for future publication. 'Although the decision to discontinue bexotegrast in IPF is disappointing for us and the many patients in need of new treatment options, we believe it is the right decision to protect patient safety,' said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. 'We sincerely thank all patients, their caregivers, the study investigators and their research teams who were part of the BEACON-IPF clinical program for their extensive efforts.' Oncology Phase 1 Enrollment Continues PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, designed to block TGF-β activation in the tumor microenvironment. PLN-101095 is currently undergoing a Phase 1 open-label trial as monotherapy and in combination with pembrolizumab in patients with solid tumors that are resistant to immune checkpoint inhibitors. In March, the Company announced interim results from this trial showing that PLN-101095 was generally well tolerated with confirmed partial responses in 50% of patients at highest dose tested to date, across multiple tumor types. The trial is currently enrolling the fifth of five planned dose cohorts. Early Programs Supported by Proprietary Platform The Company's drug discovery platform consists of a proprietary library of over 15,000 integrin binding molecules, a comprehensive screening assay system (binding, integrin confirmation, ligand-induced internalization) and an advanced live human tissue program. The Company believes in the broad applicability of the platform across multiple disease areas including delivery of drug payloads to cells utilizing integrin receptor-binding molecules as tissue-specific delivery and internalization mechanisms. About Pliant Therapeutics, Inc. Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of integrin-based therapeutics. Pliant is conducting a Phase 1 study for PLN-101095, a small molecule, dual-selective inhibitor of α v ß 8 and α v ß 1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α 7 β 1 targeting muscular dystrophies. Pliant's early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules. For additional information, please visit: Follow us on social media X, LinkedIn and Facebook. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'may,' 'will,' 'expect,' 'anticipate,' 'estimate,' 'intend,' and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those regarding development plans for PLN-101095, PLN-101325 and the Company's proprietary platform; and the Company's efforts to align its workforce and operations for its next steps. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Pliant Therapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those related to the development and commercialization of our product candidates, including any delays in our ongoing or planned preclinical or clinical trials, the impact of current macroeconomic, geopolitical and marketplace conditions on our business, operations, clinical supply and plans, our reliance on single-source third parties located in foreign jurisdictions, including China, for critical aspects of our development operations, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, including the availability of additional term loans under our loan facility, and our ability to obtain and maintain intellectual property protection for our product candidates. These and additional risks are discussed in the sections titled 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in our Quarterly Report on Form 10-Q for the period ended March 31, 2025 which are available on the SEC's website at Unless otherwise noted, Pliant is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. Investor and Media Contact: Christopher KeenanVice President, Investor Relations and Corporate CommunicationsPliant Therapeutics, Inc. [email protected]
Business Wire
12 hours ago
- Business Wire
Align Technology Connects With Over 2,000 Doctors and Practice Staff at the 2025 Invisalign ® Asia Pacific (APAC) Summit
BANGKOK--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign ® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today shared highlights from the 2025 Invisalign ® Asia Pacific ('APAC') Summit held in Bangkok, Thailand, June 5 – 7, 2025. 'With more than 3 million Invisalign smiles across Asia Pacific, we know that this region sees some of the toughest clinical challenges in the field of dentistry,' said David Carr, Align executive vice president and managing director, APAC. 'The 2025 Invisalign Asia Pacific Summit underscores the importance of continued innovation and education. We are committed to working in partnership with doctors across the region in developing Invisalign treatment protocols that can help them transform smiles and change lives for even more patients.' Over three days, more than 2,000 doctors, practice team members, partners, and Align staff from across the region came together to explore the latest innovations in digital orthodontics and restorative dentistry. The summit featured over 60 expert speakers and more than 50 immersive breakout lectures and hands-on workshops, all designed to help doctors elevate clinical outcomes, streamline workflows, and grow their practices. Key topics covered include kids and teen, complex treatments, comprehensive dentistry and practice growth. 'This meeting provided us with a platform to connect with doctors across the full Asia Pacific region, encourage ongoing learning and sharing and showcase how our global innovations can support doctors in this market,' said Gigi Tsui, Align senior director, clinical, APAC. 'As we celebrate 20 million Invisalign smiles globally, including 3 million Invisalign smiles across the Asia Pacific region, it's critical that we continue to engage doctors for feedback and insights. This is fundamental to developing new innovations that meet the unique needs of doctors and patients across this region.' Attendees explored new developments across multiple interactive zones in the Innovation Hub, including: Kids and Teens: Featuring Invisalign First™, Invisalign® Palatal Expander System, and Invisalign® System with mandibular advancement featuring occlusal blocks ('MAOB'). ClinCheck® signature experience: Highlighting the 1-page Rx form (Flex Rx), preference templates, and ClinCheck ® Live Update. Comprehensive Dentistry: Showcasing iTero Lumina™ Pro dental imaging system, iTero™ intraoral scanner, Invisalign Smile Architect™, and Invisalign® Smile Video. Consumer & Branding: Demonstrating branding and tools to help doctors raise awareness of digital treatment options among patients of all ages. Clinical Excellence: Sharing clinical tools, evidence-based resources, education and insights available to doctors and staff. The summit also featured a Women Leadership session and provider recognition and lifetime achievement awardees. In addition to the core Asia Pacific Invisalign Summit, over 300 delegates across 78 universities also attended the Align APAC University Forum hosted at the renowned Chulalongkorn University in Bangkok. The forum served as a dynamic platform for cross-border collaboration and meaningful dialogue on how Align's evidence-based approach and cutting-edge innovations complements academic excellence and clinical training. Key highlights included keynote presentations by industry experts, interactive case-based discussions, resident showcases, and panels on integrating aligner therapy into university curriculum. The event also celebrated academic excellence with the APAC Case Challenge and Align research awards for APAC, while fostering peer-to-peer collaboration and inspiring the next generation of orthodontic leaders. About Align Technology, Inc. Align Technology designs and manufactures the Invisalign ® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 281.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.1 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
